Appendix
← Clinical Reader
Obstetrics and Gynecology

Primary Ovarian Insufficiency

Primary ovarian insufficiency (POI) is a disease that affects women less than 40 years of age. Commonly, women present with amenorrhea for 4-6 months, low estradiol levels, and elevated follicle-stimulating hormone (FSH) level. POI affects mental health, fertility, cardiovascular health, and bone health. This article outlines the evaluation, diagnosis, treatment, and management of primary ovarian insufficiency. In addition, it reviews the role of the interprofessional team in managing and improv

v1 · Reviewed Nov 7, 2026 by Automated Clinical Reviewer (Strict Verbatim v1)
  • In the setting of secondary amenorrhea, first and foremost, a pregnancy test must be completed to exclude pregnancy.
  • As a result, it is of great importance for POI to be recognized early within its disease process in order to prevent and reduce the morbidity and mortality associated with hypoestrogenemia and to increase the quality of life of the women affected.
  • The typical onset of POI is in women less than 40 years of age and is diagnosed in the setting of amenorrhea lasting 4-6 months in combination with elevated follicle-stimulating hormone (FSH) and decreased estradiol levels obtained 1 month apart.
  • In patients with primary amenorrhea, evaluation should begin with karyotyping to evaluate for genetic abnormalities such as Turner syndrome.
  • In the setting of secondary amenorrhea, first and foremost, a pregnancy test must be completed to exclude pregnancy.
  • It would be appropriate to order various laboratory tests, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), and prolactin, to aid in the evaluation and diagnosis of an endocrine abnormality.
  • If all laboratory work excluding FSH is within normal limits, POI can be diagnosed in the setting of 4-6 months of amenorrhea in association with two elevated menopausal range FSH values (>40 IU/I) obtained 30 days apart.
  • Antimullerian hormone (AMH) can be measured and used as a marker of ovarian reserve, but it is not part of the diagnostic criteria for POI.
  • If on the physical exam there is evidence of hyperandrogenism, such as hirsutism, acne, clitoromegaly, or male pattern baldness, then it would be appropriate to evaluate the levels of 17-hydroxyprogesterone (21-hydroxylase antibodies), testosterone, and DHEA-S.
  • Treatment of POI is largely based on estrogen replacement to diminish vasomotor symptoms, maintain bone density, reduce fracture risk, decrease cardiovascular and autoimmune morbidity and mortality, protect cognitive function, and improve the overall well-being of affected patients.
  • The objective of treatment is to ensure that women diagnosed with POI maintain a daily level of 100 pg/mL of estradiol, as do premenopausal women with normal ovarian function.
  • The mainstay of treatment for POI remains estradiol (17B-E2) replacement via transvaginal application or transdermal patches, as both routes decrease the overall risk of venous thromboembolism (VTE) compared with oral estrogen replacement.
  • In premenopausal women, it is imperative to include progesterone supplementation for the prevention of endometrial hyperplasia and the possibility of progression to endometrial carcinoma.
Oral progesterone
Oral
Adult
200 mg
Renal
Not specified in source
Duration
Daily for 10-14 days per month
Dihydrogesterone
Oral
Adult
10-20 mg
Renal
Not specified in source
Duration
Daily for 10-14 days per month
Norethisterone
Oral
Adult
1-5 mg
Renal
Not specified in source
Duration
Daily for 10-14 days per month
Norethisterone
Transdermal
Adult
0.25 mg
Renal
Not specified in source
Duration
Two times per day for 14 days per month
  • In women with POI who are status post hysterectomy, it is appropriate to utilize estrogen therapy alone.
  • In women with vaginal atrophy, dyspareunia, or vaginal dryness/itching/irritation, topical estrogen creams may be applied for symptomatic relief or improvement.
  • Regarding assisted reproduction and fertility, there is no evidence that ovulation induction can be reliably achieved with gonadotropins or GnRH analogs.
  • Spontaneous ovulation in women with POI has shown the greatest success in pregnancy.
  • Ultimately, oocyte donation in women with POI remains the highest probability of achieving pregnancy.
  • In the future, the etiology of POI may be further defined, and additional treatment regimens may be developed to enhance fertility.
  • For example, in a study, daily DHEA and melatonin supplementation in combination with HRT showed a slight increase in successful pregnancy rates as compared to women on HRT therapy alone.
  • Symptoms of POI, such as hot flashes, mood irritability, night sweats, sleep disturbance, vaginal dryness/irritation, and dyspareunia, can be a nuisance for women.
  • Hormone replacement incurs potential complications that can be devastating, including increased incidence of deep venous thrombosis, pulmonary embolism, and cerebrovascular accidents.
  • Other long-term complications stemming from POI include decreased global cognitive function and decreased bone mineral density, leading to osteoporosis, osteopenia, and increased fracture risk.
  • Overall, the greatest health impact of POI affects a woman’s cardiovascular health, leading to early mortality from ischemic heart disease.
  • As previously discussed, infertility from POI can cause lasting psychosocial effects (anxiety, depression, sexual disorders) and impair overall well-being.
  • Patients with POI require close follow-up to ensure they are receiving the necessary hormonal replacement and are not having complications of such medications.
  • With proper estrogen replacement, women with POI can live healthy, long lives.
  • review
    Primary Ovarian Insufficiency. StatPearls [Internet] — Natalia Sopiarz, Paul B. Sparzak — StatPearls Publishing, 2023

Decision support only. Verify against local protocols and current labeling. Source: www.ncbi.nlm.nih.gov